.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chubb
Teva
Merck
Novartis
Julphar
Johnson and Johnson
Dow
Mallinckrodt
QuintilesIMS

Generated: December 16, 2017

DrugPatentWatch Database Preview

FESOTERODINE FUMARATE Drug Profile

« Back to Dashboard

When do Fesoterodine Fumarate patents expire, and what generic alternatives are available?

Fesoterodine Fumarate is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, and Zydus Pharms Usa Inc. and is included in three NDAs.

The generic ingredient in FESOTERODINE FUMARATE is fesoterodine fumarate. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. There are nine tentative approvals for this compound. Additional details are available on the fesoterodine fumarate profile page.

Summary for FESOTERODINE FUMARATE

Drug patent expirations by year for FESOTERODINE FUMARATE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alkem Labs LtdFESOTERODINE FUMARATEfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL204827-001Dec 10, 2015DISCNNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdFESOTERODINE FUMARATEfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL205007-002Feb 17, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Alkem Labs LtdFESOTERODINE FUMARATEfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL204827-002Dec 10, 2015DISCNNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdFESOTERODINE FUMARATEfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL205007-001Feb 17, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa IncFESOTERODINE FUMARATEfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL204946-002Oct 3, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa IncFESOTERODINE FUMARATEfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL204946-001Oct 3, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Novartis
Accenture
Queensland Health
Express Scripts
Harvard Business School
Mallinckrodt
Medtronic
Chubb
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot